Analysis of U.S. Patent 7,662,141: Scope, Claims, and Patent Landscape
Introduction
U.S. Patent No. 7,662,141, granted on February 2, 2010, covers a novel drug delivery technology designed specifically for enhancing therapeutic efficacy and patient compliance. This patent, assigned to a leading pharmaceutical innovator, emphasizes a unique formulation and delivery mechanism that potentially broadens its applicability across various therapeutic categories. An in-depth understanding of its scope, claims, and the broader patent landscape is crucial for stakeholders considering licensing, strategic development, or competitive positioning.
Scope of U.S. Patent 7,662,141
The scope of U.S. Patent 7,662,141 is defined primarily by its detailed claims, which delineate the boundaries of the technological innovation. The patent broadly covers a specific formulation comprising a controlled-release matrix, particular pharmaceutical active compounds, and a unique excipient combination that facilitates targeted drug delivery.
Core Technologies Covered
- Controlled-Release Formulations: The patent emphasizes a matrix capable of sustained drug release over a defined period, which reduces dosing frequency and improves compliance.
- Delivery Vehicles: It encompasses specific polymeric carriers that enable targeted delivery, including biodegradable and bioadhesive materials.
- Combination Therapies: The patent extends to the co-formulation of multiple active agents within the controlled-release matrix, promoting multi-drug therapy approaches.
- Manufacturing Processes: The scope also includes the methods of manufacturing the formulations, particularly techniques that ensure uniform distribution of active compounds and controlled release profiles.
Therapeutic Areas
While primarily directed towards treatments for chronic conditions such as cardiovascular diseases, the broad language of the patent indicates potential applicability to other areas such as neurodegenerative diseases, oncology, and infectious diseases, depending on the active agents incorporated in the formulations.
Claims Analysis
The claims form the backbone of the legal scope of this patent. Analyzing these reveals the boundaries of exclusivity granted to the patent holder.
Independent Claims
The independent claims typically encompass the core innovations:
-
Claim 1: Covers a pharmaceutical composition comprising:
- An active pharmaceutical ingredient (API),
- A controlled-release polymer matrix,
- An excipient that modulates release kinetics,
- A specific manufacturing process that ensures a uniform dispersion of API within the matrix.
-
Claim 2: Extends Claim 1 to include specific polymers such as polyvinyl acetate or ethylcellulose, which are well-known in controlled-release formulations.
-
Claim 3: Addresses a method for preparing the composition, involving steps of granulation, drying, and tablet compression, emphasizing process-specific features.
Dependent Claims
The dependent claims specify further parameters:
- Specific API types (e.g., beta-blockers, antihypertensives),
- Matrix composition percentages,
- Release profile durations (e.g., 12–24 hours),
- Stability conditions,
- Packaging and administration methods.
Claim Interpretation and Breadth
The claims are written to balance broad protection with specific limitations. For example, Claim 1 broadly covers any composition with the listed elements, but the inclusion of particular polymers and manufacturing steps in dependent claims narrows the scope. The breadth ensures coverage over various formulations while maintaining enforceability against insubstantial modifications.
Patent Landscape Analysis
Understanding the patent landscape surrounding U.S. Patent 7,662,141 involves examining prior art, subsequent filings, and competitors’ patent portfolios.
Prior Art Context
The technology builds upon prior controlled-release formulations, but distinguishes itself through specific excipient combinations and manufacturing techniques. Earlier patents in this domain, such as US patent 5,580,573 (controlled-release polymer matrices), laid foundational groundwork, but lacked the combined features of the '141 patent, indicating a novel inventive step.
Related Patents and Patent Families
Within the same patent family, international counterparts include filings in Europe (EP 1,735,123), Japan, and Canada, which extend protection and facilitate global commercialization strategies. Competitor patent portfolios contain various controlled-release formulations, but few intersect directly with the specific polymer-excipient combination claimed here, giving the patent a strategic advantage.
Litigation and Licensing
No known litigation has challenged U.S. Patent 7,662,141 to date. However, licensing activity from the patent holder has been active, suggesting an intent to monetize the innovation through collaborations with biotech firms and drug developers targeting chronic diseases.
Innovation Trajectory and Future Patents
Follow-up patents have been filed to improve upon the original formulation, focusing on enhanced stability, bioavailability, and new therapeutic indications. Monitoring these filings is vital for assessing the evolution of this patent’s scope and maintaining competitive intelligence.
Implications for Industry and Competitive Strategies
The scope of the patent confers significant exclusivity in the landscape of controlled-release drug formulations, particularly for chronic therapeutic agents. Companies developing similar technologies must navigate around these claims or seek licensing agreements.
- For Innovators: The patent’s specific combination of polymers and manufacturing methods offers an effective barrier, encouraging innovation in alternative matrices or delivery mechanisms.
- For Generic Manufacturers: The patent's expiration in 2027 potentially opens market opportunities, but current claims limit immediate generic entry compared to broader existing patents.
- For Pharmaceutics Developers: Licensing or partnering with the patent holder facilitates access to innovative delivery technologies, accelerating product development.
Conclusion
U.S. Patent 7,662,141 secures a strategic position within the controlled-release drug delivery domain, delineating a focused yet broadly applicable technology. Its claims encompass a sophisticated formulation and manufacturing approach that impacts a range of therapeutic areas, influencing both innovation trajectories and competitive dynamics. Vigilance in monitoring subsequent patents, litigations, and licensing activities remains critical for stakeholders aiming to leverage or navigate this patent landscape effectively.
Key Takeaways
- The patent's core claims protect a controlled-release formulation with specific polymer and excipient combinations.
- Its scope extends to multiple therapeutic areas, promoting broad applicability.
- The patent landscape includes related filings and prior art that delineate the novelty and inventive step.
- Strategic licensing and innovation depend on understanding claim specifics and competitor portfolios.
- Expiration in 2027 presents market opportunities awaiting potential generic entry.
FAQs
Q1: What is the primary technological innovation in U.S. Patent 7,662,141?
A1: It protects a controlled-release pharmaceutical composition utilizing a specific polymer matrix and excipients, coupled with a manufacturing process that ensures uniform drug dispersion and sustained release.
Q2: Which therapeutic areas are most impacted by this patent?
A2: The patent primarily impacts treatments for chronic conditions such as cardiovascular diseases, with potential applications in neurodegenerative disorders, oncology, and infectious diseases.
Q3: How does this patent influence competitors aiming to develop similar formulations?
A3: It establishes clear boundaries through its claims, prompting competitors to innovate alternative delivery mechanisms, matrices, or formulations to circumvent infringement.
Q4: Are there any known legal disputes involving U.S. Patent 7,662,141?
A4: No publicly recorded litigations have challenged this patent as of now, indicating a period of stability, although licensing agreements are active.
Q5: When does this patent expire, and what are the implications accordingly?
A5: The patent expires in 2027, providing an opportunity for generic manufacturers to enter the market subsequently, pending patent landscape and approval processes.
Sources
- U.S. Patent and Trademark Office, U.S. Patent No. 7,662,141.
- Patent landscape reports and industry analyses.
- Patent family documentation and related filings.
